PP_1170x120_10-25-21

Neurelis president and CEO Craig Chambliss.

FDA approves nasal spray for epilepsy treatment

FDA approves nasal spray for epilepsy treatment

SAN DIEGO, Calif. – Neurelis announced Monday that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in people with epilepsy 6 years of